TABLE 6

Scheme B: MRTcell as functions of CLint,sec, CLd1, CLd2, ka, and nonlinear metabolism (Km of 50 μM and Vmax of 50 nmol/min). Initial drug concentrations of 100 and 300 μM were used; eq. 2 was used to estimate the MRT.


Cln

CLint,sec

MRTcell (min) at ka = 1 min-1

MRTcell (min) at ka = 30 min-1
CLd1 = CLd2 (0.02 ml/min)
CLd1 = CLd2 (0.5 ml/min)
CLd1 = CLd2 (1 ml/min)
CLd1 = CLd2 (5 ml/min)
CLd1 = CLd2 (0.02 ml/min)
CLd1 = CLd2 (0.5 ml/min)
CLd1 = CLd2 (1 ml/min)
CLd1 = CLd2 (5 ml/min)
μM ml/min
Apical Administration
100 1 8.49 6.72 6.38 5.98 25.1* 8.22* 6.18* 4.62
100 5 11.0 10.5 10.4 10.2 17.8* 7.52* 6.15* 4.74
100 10 15.8 15.5 15.4 15.3 13.8* 7.05* 6.08* 4.90
300 1 16.6* 9.82 9.25 8.85 49.2* 10.1* 8.62 7.60
300 5 15.0* 13.4 13.2 13.0 37.7* 9.87* 8.66 7.74
300 10 19.2* 18.4 18.3 18.2 29.9* 9.75* 8.72 7.91
Basolateral Administration
100 1 132 10.1 8.05 6.71 131 9.01 6.99 5.59
100 5 136 14.4 12.3 11.0 131 9.10 7.10 5.72
100 10 141 19.6 17.4 16.1 131 9.24 7.25 5.90
300 1 132 13.7 12.4 11.7 131 12.6 11.4 10.7
300 5 136 18.2 16.6 15.8 131 12.7 11.5 10.8
300
10
141
23.6
21.9
20.9
131
12.9
11.7
10.9
  • * Deviating trend: increasing values of CLint,sec failed to increase the MRT